Long term effect of intravenous immunoglobulins and oral cyclophosphamide in multifocal motor neuropathy

Objectives—To report the long term effect of the combined treatment with high dose intravenous immunoglobulins (IVIg) and oral cyclophosphamide (CTX) in patients with multifocal motor neuropathy, and to determine whether the association of oral CTX in these patients may help to delay and, possibly, suspend IVIg infusions. METHODS Six patients with multifocal motor neuropathy responding to an initial course of IVIg (0.4 g/kg/day for five consecutive days) were followed up for 37 to 61 (mean 47) months. All patients were subsequently treated with periodic IVIg infusions (0.4 g/kg/day for two days at clinical worsening) and oral CTX (1-3 mg/kg/day). Improvement was assessed using the Rankin disability scale, a functional impairment scale for upper and lower limbs, and the MRC rating scale on the 20 most affected muscles. Electrophysiological and antiglycolipid antibody studies were performed before treatment, then yearly during follow up. RESULTS All patients improved during treatment and, by the end of follow up or before worsening after therapy suspension, the median Rankin (P=0.0335) and upper (P=0.0015) and lower limb (P=0.0301) impairment scores and the mean MRC (P=0.0561) score were improved. By that time the number of nerves with partial motor conduction block was reduced (P=0.0197) and antiglycolipid antibody titres had decreased in all but one patient. All patients required periodic IVIg infusions to maintain improvement but, after three to seven months of oral CTX, the interval between IVIg infusions could be progressively prolonged until, in three patients, both treatments could be stopped for up to two years before clinical worsening. The main complications, both related to oral CTX, were haemorrhagic cystitis in two patients and persistent amenorrhea in one patient. Conclusions—IVIg can induce and maintain improvement in multifocal motor neuropathy but does not eradicate the disease. Oral CTX may help to induce a sustained remission but it is not devoid of side effects and might therefore be reserved for patients with multifocal motor neuropathy who require frequent IVIg infusions to maintain improvement.

[1]  S. Barbieri,et al.  Multifocal motor neuropathy: A source of error in the serial evaluation of conduction block , 1996, Muscle & nerve.

[2]  L. H. van den Berg,et al.  Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study. , 1995, Journal of neurology, neurosurgery, and psychiatry.

[3]  V. Meininger,et al.  Multifocal motor neuropathy with conduction block: a study of 24 patients. , 1995, Journal of neurology, neurosurgery, and psychiatry.

[4]  A. Pestronk,et al.  Chronic motor neuropathies: Diagnosis, therapy, and pathogenesis , 1995, Annals of neurology.

[5]  L. H. van den Berg,et al.  Improvement of multifocal motor neuropathy during long‐term weekly treatment with human immunoglobulin , 1995, Neurology.

[6]  A. Pestronk,et al.  Progression of multifocal motor neuropathy during apparently successful treatment with human immunoglobulin , 1994, Neurology.

[7]  O. Blin,et al.  Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti‐GM1 antibodies , 1994, Neurology.

[8]  J. Griffin,et al.  Multifocal motor neuropathy: Electrodiagnostic features , 1994, Muscle & nerve.

[9]  S. Barbieri,et al.  High‐dose intravenous immunoglobulin therapy in multifocal motor neuropathy , 1993, Neurology.

[10]  Robert G. Miller,et al.  Multifocal motor neuropathy: Response to human immune globulin , 1993 .

[11]  A. Pestronk,et al.  Immunosuppressive treatment in multifocal motor neuropathy , 1991, Annals of neurology.

[12]  G. Legname,et al.  Anti‐GM1 IgM antibodies in motor neuron disease and neuropathy , 1990, Neurology.

[13]  A. Pestronk,et al.  A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside , 1988, Annals of neurology.

[14]  G. Parry,et al.  Multifocal acquired demyelinating neuropathy masqurading as motor neuron disease , 1988, Muscle & nerve.

[15]  D. Chad,et al.  Slow resolution of multifocal weakness and fasciculation , 1986, Neurology.

[16]  L. Goodman,et al.  THE PHARMACOLOGICAL BASIS OF THERAPEUTICS , 1966 .

[17]  M. Magistris,et al.  Motor neuropathy with proximal multifocal persistent conduction block, fasciculations and myokymia. Evolution to tetraplegia. , 1986, European neurology.